BD (NYSE:BDX) announced today that it appointed Simon Campion as EVP and president of the company’s medical segment.
Franklin Lakes, New Jersey-based BD announced in March that Alberto Mas, who held the same roles Campion will assume, intended to retire. Campion’s position will be made effective on July 1, 2022.
Mas, 60, informed the company of his intent to retire in a move that will be made effective at the end of the company’s fiscal year on Sept. 30, 2022. He spent a total of nearly 30 years at BD across a number of leadership positions.
Campion will report to Chair, CEO and President Tom Polen and his responsibilities include global strategic, operational and commercial performance for the medical segment at BD, according to a news release. He has served as EVP and president of the interventional segment for BD since September 2018 and will continue to lead that business in the interim until the company names a successor.
Before leading the interventional segment, Campion held leadership roles in a number of businesses at Bard since 2008, before he integrated legacy Bard and BD product platforms into an integrated surgery offering as president of BD’s surgery business unit. Before Bard, he held marketing and R&D roles at Cook Medical and Boston Scientific.
“Simon is a proven business leader with excellent strategic and operational skills and deep global experience,” Polen said in the release. “Since joining BD from the Bard acquisition, Simon has been integral in the integration and growth of the legacy Bard businesses across the Interventional segment and is well positioned to lead BD’s largest segment.”
